ANGPTL1: A Potential Drug Target and Biomarker (G9068)

Target Name: ANGPTL1

NCBI ID: G9068

ANGPTL1

ANGPTL1: A Potential Drug Target and Biomarker

Introduction

Angioarrestin (ANGPTL1) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the A-type ATP-binding proteins (APBPs) family, which includes several other well-known proteins, such as APB1 and APB2. These proteins are involved in various physiological processes in the body, including blood pressure, blood flow, and cellular signaling.

One of the unique features of ANGPTL1 is its ability to regulate the blood pressure. It has been shown to have a positive correlation with blood pressure in both humans and animals, and experiments have suggested that ANGPTL1 may be a potential drug target for hypertension.

Targeting ANGPTL1

Despite the potential benefits of ANGPTL1 as a drug target, much research is still needed to fully understand its biology and how it can be targeted. One approach that researchers have taken to target ANGPTL1 is to use small molecules to interfere with its activity.

One of the most promising small molecules that has been shown to interact with ANGPTL1 is called NPC1 (N-acetyl-L-cysteine). NPC1 is a known inhibitor of ANGPTL1, and experiments have suggested that it may be a useful drug candidate for hypertension.

In addition to NPC1, researchers have also shown interest in targeting ANGPTL1 using other small molecules, such as Pteridine and Eprinex. These drugs have been shown to reduce hypertension in animal experiments and have potential clinical value.

Measuring ANGPTL1

To fully understand the biology of ANGPTL1, researchers have also been interested in measuring its levels in various tissues and body fluids. Several studies have shown that ANGPTL1 is expressed in various tissues of the body, including the brain, heart, kidneys, and liver.

One of the challenges in measuring ANGPTL1 is its low protein stability. ANGPTL1 has a relatively short half-life of only 10-15 minutes, which makes it difficult to measure its levels in various tissues and body fluids over time.

However, researchers have been able to measure ANGPTL1 levels in several body fluids, including blood, saliva, and urine. In blood, ANGPTL1 has been shown to have a correlation with systolic and diastolic blood pressure, which suggests that it may be involved in regulating blood pressure.

Angioarrestin as a potential drug target

Despite the promising results of ANGPTL1 research, much work is still needed to fully understand its biology and potential as a drug target. ANGPTL1 has been shown to have a positive correlation with blood pressure in both humans and animals, and it is possible that it may be a useful target for hypertension.

Targeting ANGPTL1 using small molecules, such as NPC1, ferralibine and eplerenone, has achieved certain results in animal experiments. These drugs have shown potential to reduce hypertension and have potential clinical value.

Conclusion

ANGPTL1 is a protein that is expressed in various tissues of the body, and it has been shown to have a positive correlation with blood pressure in both humans and animals. As a result, ANGPTL1 has generated a lot of interest as a potential drug target for hypertension.

Currently, researchers are exploring the use of small molecule compounds, such as NPC1, ferralibine, and eplerenone, to interfere with the activity of ANGPTL1 to reduce hypertension in animal experiments. Results showed that these drugs were shown to reduce

Protein Name: Angiopoietin Like 1

The "ANGPTL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANGPTL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets